Nevertheless, their findings suggest that EGFR+/ALK+ NSCLC patients could also benefit from ICI, especially EGFR+ patients with ≥25% PD-L1-expressing tumor cells. This evidence concerns the gene CD274 and non-small cell lung carcinoma.